Skip to main content

Table 3 Results of multivariate Cox analyses of clinical and molecular variables

From: CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients

Criteria

PFS

OS

HR

95% CI

P

HR

95% CI

p

FIGO I/II versus III/IV (n = 19 vs 158)

5.029

2.029–12.46

0.001

2.08

0.998–4.333

0.051

Resection R0 versus R1/2 (n = 41 vs 136)

1.865

1.257–2.766

0.002

2.453

1.591–3.781

0.001

CAMK2N1 U versus M (n = 162 vs 15)

1.408

0.789–2.512

0.246

1.300

0.670–2.524

0.438

KRT86 U versus M (n = 138 vs 39)

1.477

0.992–2.201

0.055

1.243

0.787–1.964

0.351

CAMK2N1/KRT86 U versus M (n = 129 vs 48)

1.416

0.965–2.077

0.075

1.214

0.788–1.871

0.379

CAMK2N1/RUNX3 U versus M (n = 147 vs 32)

1.587

1.031–2.442

0.036

1.602

1.017–2.542

0.042

CAMK2N1/KRT86/RUNX3 U versus M (n = 119 vs 58)

1.543

1.070–2.223

0.020

1.348

0.903–2.012

0.144

  1. Analyses included clinical variables and one of the molecular markers. Data for clinical variables are exemplarily and result from the analysis with CAMK2N1/RUNX3. LogRank test results with significance are marked in bold. U, unmethylated; M, methylated. Marker combinations are positive (methylated) if at least one single marker is methylated (<OR> combinations) otherwise the combination is scored as unmethylated
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us